ZANTAC 150
LOE ApproachingNDAORALCAPSULE
Approved
Mar 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 11h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZANTAC 150 is an oral capsule small-molecule histamine H2-receptor antagonist approved in 1994 for gastrointestinal indications. The drug reduces gastric acid secretion and is used to treat acid-reflux conditions. Generic ranitidine formulations have long dominated this market segment.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100) signals declining team scope and emphasis on cost management and legacy support rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Bioavailability Study of Ranitidine Hydrochloride (Maximum Strength ZANTAC 150®) Compared to Two Different 150 mg Ranitidine Hydrochloride Oral Disintegrating Tablet (ODT) in Fasting, Healthy Male Volunteers
Started May 2009
42 enrolled
Healthy
Career Relevance
Working on ZANTAC 150 offers limited career growth potential given the approaching loss of exclusivity, zero linked job openings, and mature lifecycle stage. Roles are primarily defensive and focused on managing decline rather than driving innovation or market expansion, making this assignment more suitable for stabilizing revenue than building career momentum.
Brand Manager (Legacy/Defensive)
Worked on ZANTAC 150 at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.